OR WAIT 15 SECS
Beckman Coulter Life Sciences
Beckman Coulter Life Sciences, a Danaher company, develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing. We are at the heart of discovery, assisting the world's biomedical researchers with solutions that simplify complex processes, automate procedures, and innovate novel detection and analysis methods along the discovery path. But, delivering innovation begins with the voice of the customer. By listening to our customers' needs, we develop the products that fuel groundbreaking research, ensure uncompromising quality, and enable efficiency. The breadth of product solutions is as diverse as the customer segment that makes up Life Sciences in today's world. From particle characterization for industrial use, to monitoring drug therapies for cancer patients, we design products of the highest quality and continually reach into the future for better solutions to support the advancement of science. Scientists use our research systems to study complex biological problems including causes of disease and the development of new therapies or drugs. Our research customers include pharmaceutical and biotechnology companies, medical schools, and research institutions. For more than 80 years our products have been making a difference in people's lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health, and reducing the cost of care.
Beckman Coulter Life Science's product portfolio includes a vast array of systems, reagents and services in flow cytometry and cell sorting, particle characterization, centrifugation, automation, genomic isolation/clean-up and analysis, and bioseparations. As the leader in capillary electrophoresis (CE) technology, we provide solutions for separation and characterization of molecules including proteins, peptides, carbohydrates, ions, nucleic acids, basic drugs, and enantiomers with high efficiency and eproducibility. CE solutions include the new CESI 8000 High Performance Separation-ESI Module with OptiMS technology, the PA 800 plus Pharmaceutical Analysis System, and the P/ACE MDQ.
The CESI 8000 incorporates OptiMS technology, fully integrating the high efficiency and ultra-low flow characteristics of CE with electrospray ionization (ESI) in a single dynamic process within the same device. Reduction of flow with ESI into the low nanoflow region serves to significantly improve ionization efficiency as well as reduce ion suppression of co-migrating analytes. With CESI we are able to generate stable and robust electrospray with bulk flows of electrolyte at or below 10 nL/min, that when combined with the orthogonal selectivity provided by CE allows for increased coverage and sensitivity.
Beckman Coulter's XL-A/XL-I Analytical Ultracentrifuge with native condition capability provides the ideal solution to satisfying the demands of the drug discovery process by characterizing a protein's behavior in free solution under physiological concentrations, temperatures, and buffer conditions.
Beckman Coulter Life Sciences has sales, marketing, and service associates positioned throughout the world, in over 130 sites, ready to provide customers with first class support when they need it. Product development and manufacturing is also global, with sites in France, Ireland, Massachusetts, Florida, Indiana, Colorado, and California.
250 South Kraemer Blvd.
Brea, CA 92821
NUMBER OF EMPLOYEES